Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

LipoScience Nearly Back To Square One

LipoScience (NASDAQ:LPDX) has developed a blood test (NMR LipoProfile) that has the potential to meaningfully improve outcomes for patients at risk of cholesterol-related cardiovascular problems, but it takes more than an FDA-approved test to make a business work. LipoScience is perilously close to becoming a company with a great future in its past, as the company continues to struggle to generate commercial interest in its test. A journal article based upon a retrospective analysis of LDL-P measurement could help spur interest and a takeover is a credible potential outcome, but LipoScience's current circumstances make this a highly speculative stock.

Can Q1 Become The Bottom?

After a drawn out and pretty ugly process of revisions, it looks like the...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details